Drug Profile
Research programme: proto oncogene protein c-myc inhibitors - Peptomyc
Alternative Names: OMO-101; Omomyc-based cell penetrating peptides - Peptomyc; Omomyc-CPPLatest Information Update: 20 Dec 2022
Price :
$50
*
At a glance
- Originator Peptomyc; Vall d-Hebron Research Institute
- Class Antineoplastics; Peptides
- Mechanism of Action Proto oncogene protein c-myc inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer